Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.
2.

Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Callister SM, Jobe DA, Agger WA, Schell RF, Kowalski TJ, Lovrich SD, Marks JA.

Clin Diagn Lab Immunol. 2002 Jul;9(4):908-12.

3.

Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components.

Lusitani D, Malawista SE, Montgomery RR.

J Infect Dis. 2002 Mar 15;185(6):797-804. Epub 2002 Feb 20.

PMID:
11920297
4.

Conformational nature of the Borrelia burgdorferi decorin binding protein A epitopes that elicit protective antibodies.

Ulbrandt ND, Cassatt DR, Patel NK, Roberts WC, Bachy CM, Fazenbaker CA, Hanson MS.

Infect Immun. 2001 Aug;69(8):4799-807.

5.

Crystal structure of outer surface protein C (OspC) from the Lyme disease spirochete, Borrelia burgdorferi.

Kumaran D, Eswaramoorthy S, Luft BJ, Koide S, Dunn JJ, Lawson CL, Swaminathan S.

EMBO J. 2001 Mar 1;20(5):971-8.

6.

Crystal structure of Lyme disease antigen outer surface protein C from Borrelia burgdorferi.

Eicken C, Sharma V, Klabunde T, Owens RT, Pikas DS, Höök M, Sacchettini JC.

J Biol Chem. 2001 Mar 30;276(13):10010-5. Epub 2001 Jan 3.

7.

Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant.

Kraiczy P, Hunfeld KP, Peters S, Würzner R, Ackert G, Wilske B, Brade V.

J Med Microbiol. 2000 Oct;49(10):917-28.

PMID:
11023189
8.

Specific immune response to a synthetic peptide derived from outer surface protein C of Borrelia burgdorferi predicts protective borreliacidal antibodies.

Ikushima M, Matsui K, Yamada F, Kawahashi S, Nishikawa SK.

FEMS Immunol Med Microbiol. 2000 Sep;29(1):15-21.

10.

Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both.

Luke CJ, Marshall MA, Zahradnik JM, Bybel M, Menefee BE, Barbour AG.

J Infect Dis. 2000 Mar;181(3):1062-8.

PMID:
10720532
12.
13.

Evaluation of whole-cell and OspC enzyme-linked immunosorbent assays for discrimination of early lyme borreliosis from OspA vaccination.

Wieneke CA, Lovrich SD, Callister SM, Jobe DA, Marks JA, Schell RF.

J Clin Microbiol. 2000 Jan;38(1):313-7.

14.
15.

Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense.

Brown JP, Zachary JF, Teuscher C, Weis JJ, Wooten RM.

Infect Immun. 1999 Oct;67(10):5142-50.

16.

A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease.

Porwancher R.

J Infect Dis. 1999 Apr;179(4):1021-4.

PMID:
10068602
17.

Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto.

Wang IN, Dykhuizen DE, Qiu W, Dunn JJ, Bosler EM, Luft BJ.

Genetics. 1999 Jan;151(1):15-30.

19.

Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA.

J Infect Dis. 1998 Sep;178(3):733-41.

PMID:
9728542
20.

Supplemental Content

Support Center